Pulmonx Reports Second Quarter 2026 Financial Results

Pulmonx cut losses and boosted margins, but revenue shrank for another quarter.

What the company is saying

Pulmonx Corporation reports a 5% year-over-year revenue decline to $22.8 million for Q2 2026, but highlights a record gross margin of 78% and improved profitability metrics. The company frames its narrative around operational discipline, citing a 16% reduction in operating expenses to $26.8 million and a narrowed net loss of $10.1 million, or $0.24 per share. Management attributes these improvements to cost realignment efforts, though the specific impact of these actions is not quantified. Forward-looking statements project full-year 2026 revenue between $90 million and $92 million, gross margin at approximately 76%, and operating expenses of $109–111 million. The announcement emphasizes margin and cost improvements over revenue growth, with international revenue excluding China up 12%, but overall international revenue down 6%. The tone is measured and factual, with limited promotional language and no mention of new products, M&A, or leadership changes.

What the data suggests

The reported numbers confirm a mixed quarter: total revenue fell 5% to $22.8 million, with U.S. revenue down 4% and international revenue down 6%. Excluding China, international revenue rose 12%, indicating regional volatility. Gross profit increased slightly to $17.7 million, and gross margin reached a record 78%, up from 72% last year. Operating expenses dropped 16% to $26.8 million, contributing to a reduced net loss of $10.1 million versus $15.2 million a year ago. Adjusted EBITDA loss improved by 39% to $5.1 million. Cash and cash equivalents stood at $55.8 million as of June 30, 2026. Full-year guidance implies continued losses, with projected operating expenses outpacing revenue by roughly $19 million and an expected $23 million decrease in cash and marketable securities. The data is comprehensive and supports most claims, though the attribution of improvements to cost realignment is not directly broken out.

Analysis

The announcement is measured and factual, with most claims supported by detailed numerical disclosures for the quarter. The tone is neutral, focusing on both areas of improvement (gross margin, reduced losses, lower operating expenses) and areas of weakness (declining revenue). Forward-looking statements are limited to full-year 2026 guidance, which is standard for quarterly reporting and not presented in an exaggerated manner. There is no evidence of narrative inflation or overstatement; the language is proportionate to the results, and no large capital outlay is paired with only long-dated, uncertain returns. The improvement in profitability metrics is real, but as the company remains loss-making, the signal cannot be stronger than weak_positive. The gap between narrative and evidence is minimal, with only minor attribution of improvements to 'cost realignment efforts' lacking direct quantification.

Risk flags

• ●Revenue contraction is ongoing, with total worldwide revenue down 5% year-over-year and both U.S. and international segments declining. Sustained revenue shrinkage can erode scale advantages and threaten long-term viability if not reversed.
• ●Profitability improvements are driven by cost cuts rather than top-line growth. While operating expenses fell 16%, the company remains loss-making, and further expense reductions may be harder to achieve without impacting operations.
• ●The company expects to burn approximately $23 million in cash and marketable securities in 2026, with cash and equivalents at $55.8 million as of June 30, 2026. Persistent losses and cash burn raise the risk of future capital needs if revenue does not stabilize or grow.
• ●Guidance for 2026 projects continued losses, with operating expenses ($109–111 million) well above revenue ($90–92 million). This gap signals that a clear path to profitability is not yet established, and any shortfall in revenue or overrun in expenses could accelerate cash depletion.
• ●Attribution of improved losses to 'cost realignment efforts' is not directly quantified, making it difficult to assess whether these improvements are sustainable or largely one-off in nature.

Bottom line

Pulmonx's Q2 2026 results show tighter cost control and record gross margins, but revenue continues to decline and the business remains unprofitable. The company’s guidance for the full year implies further cash burn and no imminent return to profitability, with operating expenses set to outpace revenue by a wide margin. Most improvements stem from expense reductions rather than underlying business growth, and the sustainability of these gains is unclear without a turnaround in revenue trends. The cash position provides some runway, but ongoing losses could force future financing if performance does not improve. Investors should focus on whether Pulmonx can stabilize or grow revenue in coming quarters, as cost-cutting alone will not deliver a viable long-term model. The key takeaway: operational discipline is buying time, but the core growth problem remains unresolved.

Announcement summary

(NASDAQ:LUNG) Pulmonx Corporation reported total worldwide revenue of $22.8 million for the second quarter of 2026, representing a 5% decrease from $23.9 million in the second quarter of 2025 and a decrease of 6% on a constant currency basis. U.S. revenue was $14.2 million, a 4% decrease year-over-year, while international revenue was $8.6 million, a 6% decrease year-over-year and a 9% decrease on a constant currency basis; excluding China, international revenue increased 12% year-over-year and 9% on a constant currency basis. Gross profit for the quarter was $17.7 million with a record gross margin of 78%, compared to 72% in the prior year period. Operating expenses were $26.8 million, down 16% from $32.0 million in the second quarter of 2025. Net loss for the quarter was $10.1 million, or $0.24 per share, compared to a net loss of $15.2 million, or $0.38 per share, in the prior year. Adjusted EBITDA loss was $5.1 million, a reduction of 39% from $8.4 million in the second quarter of 2025. The company projects full year 2026 revenue in the range of $90 million to $92 million, gross margin of approximately 76%, and total operating expenses between $109 million and $111 million.

Disagree with this article?